{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:12:25Z","timestamp":1792602745517,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016928","name":"Instituto Nacional de Pediatria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The hydroa-vacciniforme-like lymphoproliferative disorder (HVLD) is a rare NK\/T-cell condition affecting children in Latin America and Asia. It often progresses to systemic lymphoma, with Latin American patients experiencing worse outcomes compared to East Asians. Understanding viral and host genetic interactions is crucial for advancing targeted therapies. Here, we report a male patient with HVLD successfully treated with hematopoietic stem cell transplantation, highlighting its potential as a therapeutic approach for this aggressive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>An 8-year-old boy presented with persistent skin lesions, fever, and pain. Biopsy confirmed a diagnosis of HVLD. Initial treatments with thalidomide and steroids provided temporary relief. At 12, lymphoma progression led to rituximab and CHOP chemotherapy. Further investigations revealed persistent EBV infection and lymphoma; hence, a haploidentical stem cell transplant was performed at 15. The procedure was successful, achieving complete immune reconstitution and viral clearance. Three years post-transplant, the patient remains in good health with no detectable EBV and complete vaccinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>While EBV infection is common, only specific immunodeficiency states seem to enable EBV-related lymphoproliferative disorders. The exact mechanism leading to this immunosuppressive environment in HVLD remains unclear. Clinically, HVLD resembles specific inborn errors of immunity with EBV susceptibility. Additionally, cases of GATA2 and TACI deficiency presenting with HVLD suggest a potential link to underlying immune dysfunction. Further research in this area is crucial to understand the immunological basis of HVLD. Treatment options for HVLD are diverse and lack standardized protocols. Our case demonstrates the potential of HSCT with reduced-intensity conditioning and EBV-specific T-cell infusion as an effective cure. Given the limited understanding of HVLD, an immunological approach to characterizing patient profiles and prolonged follow-up are essential. While diverse therapies exist, HSCT offers the best hope for a cure. Further research towards tailored treatment strategies holds significant promise for improved patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HVLD presents a complex and multifaceted challenge; our case demonstrates the potential of HSCT as a curative treatment. Unveiling the underlying immunology and tailoring therapies to patient profiles are crucial for improved outcomes. Further research is key to refining treatment strategies and offering hope for this rare and severe disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1511385","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:20:06Z","timestamp":1742534406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Hydroa vacciniforme-like lymphoproliferative disorder, an EBV-associated disease, successfully treated with hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Eduardo","family":"Liquidano-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibert","family":"Maza-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Yamazaki-Nakashimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Rodr\u00edguez-Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso G.","family":"Ram\u00edrez Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Bustamante-Ogando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Ernesto","family":"Cruz-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Gutierrez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marimar","family":"Saez-de-Ocariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Espinosa-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nideshda","family":"Ramirez-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma C.","family":"Scheffler-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1040-8428(00)00046-9","article-title":"Epstein\u2013Barr virus-associated Malignancies: epidemiologic patterns and etiologic implications","volume":"34","author":"Hsu","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2020.07.011","article-title":"Cytotoxicity in Epstein Barr virus specific immune control","volume":"46","author":"M\u00fcnz","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00439-020-02145-3","article-title":"Genetic susceptibility to EBV infection: insights from inborn errors of immunity","volume":"139","author":"Tangye","year":"2020","journal-title":"Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein barr virus: development of vaccines and immune cell therapy for EBV-associated diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-502203","article-title":"Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma","volume":"122","author":"Quintanilla-Martinez","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181fbb4fd","article-title":"EBV-associated cutaneous NK\/T-cell lymphoma","volume":"34","author":"Rodr\u00edguez-Pinilla","year":"2010","journal-title":"Am J Surg Pathology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0190-9622(95)90181-7","article-title":"Edematous, scarring vasculitic panniculitis: A new multisystemic disease with Malignant potential","volume":"32","author":"Ruiz-Maldonado","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"B9","first-page":"1","article-title":"Epstein-Barr Virus: Clinical and Laboratory Characteristics of Infectious Mononucleosis","volume-title":"Epstein-Barr Virus Transmission, Diagnosis and Role in the Development of Cancers","author":"Napole\u00f3n","year":"2014"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00394-22","article-title":"Epstein-barr virus genome deletions in epstein-barr virus-positive T\/NK cell lymphoproliferative diseases","volume":"96","author":"Wongwiwat","year":"2022","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135512","article-title":"HLA allele E*01:01 is associated with a reduced risk of EBV-related classical hodgkin lymphoma independently of HLA-A*01\/*02","volume":"10","author":"Mart\u00edn","year":"2015","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9314","DOI":"10.3390\/ijms21239314","article-title":"Hydroa vacciniforme and hydroa vacciniforme-like lymphoproliferative disorder: A spectrum of disease phenotypes associated with ultraviolet irradiation and chronic epstein\u2013barr virus infection","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.06.013","article-title":"Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients","volume":"99","author":"Xie","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw160","article-title":"Association of GATA2 deficiency with severe primary epstein-barr virus (EBV) infection and EBV-associated cancers","volume":"63","author":"Cohen","year":"2016","journal-title":"Clin Infect Diseases"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915986","article-title":"Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection","volume":"13","author":"Grze\u015bk","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"adv00192","DOI":"10.2340\/00015555-3556","article-title":"Hydroa vacciniforme-like lymphoproliferative disorder treated with intravenous immunoglobulin: long-term remission without haematopoietic stem cell transplantation or chemotherapy","volume":"100","author":"Ruan","year":"2020","journal-title":"Acta Dermato Venereologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785931","article-title":"How I treat T-cell chronic active Epstein-Barr virus disease","volume":"131","author":"Bollard","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13000-019-0859-4","article-title":"Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases","volume":"14","author":"Guo","year":"2019","journal-title":"Diagn Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.v11.6","article-title":"Chronic active Epstein\u2013Barr virus and hydroa vacciniforme-like lymphoproliferative disorder in a pediatric patient complicated by fatal ruptured cerebral artery aneurysm","volume":"11","author":"Yi","year":"2023","journal-title":"Clin Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005291","article-title":"High risk of relapsed disease in patients with NK\/T-cell chronic active Epstein-Barr virus disease outside of Asia","volume":"6","author":"D\u00e1vila Salda\u00f1a","year":"2022","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.176","article-title":"Long-term remission in a child with refractory EBV+ hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV+-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy","volume":"46","author":"El-Mallawany","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.026","article-title":"Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic epstein-barr virus\u2013associated T or natural killer cell lymphoproliferative diseases","volume":"20","author":"Sawada","year":"2014","journal-title":"Biol Blood Marrow Transplantation"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1511385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:20:10Z","timestamp":1742534410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1511385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1511385"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1511385","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1511385"}}